Central systolic blood pressure relates inversely to nitric oxide synthesis in young black adults: the African-PREDICT study.
Journal
Journal of human hypertension
ISSN: 1476-5527
Titre abrégé: J Hum Hypertens
Pays: England
ID NLM: 8811625
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
15
06
2020
accepted:
16
11
2020
revised:
27
10
2020
pubmed:
5
12
2020
medline:
15
12
2021
entrez:
4
12
2020
Statut:
ppublish
Résumé
Lower nitric oxide (NO) bioavailabilty associates with hypertension in patients and elderly populations. With hypertension known to develop earlier in black populations, we compared both plasma and urinary NO-related markers and their associations with central systolic blood pressure (cSBP) and arterial stiffness in healthy young black and white adults. We included healthy black and white men and women (n = 1110; 20-30 years) and measured cSBP and pulse wave velocity (PWV), along with both plasma and urinary arginine, homoarginine, asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), as well as urinary ornithine/citrulline, nitrite and nitrate. In addition, the urinary nitrate-to-nitrite ratio (U
Identifiants
pubmed: 33273698
doi: 10.1038/s41371-020-00453-9
pii: 10.1038/s41371-020-00453-9
doi:
Substances chimiques
Nitric Oxide
31C4KY9ESH
Arginine
94ZLA3W45F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
985-993Subventions
Organisme : Medical Research Council
Pays : United Kingdom
Informations de copyright
© 2020. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.
Références
Opie LH. Heart disease in Africa. Lancet. 2006;368:449–50.
doi: 10.1016/S0140-6736(06)69149-6
Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Sci Rep. 2018;8:9418.
doi: 10.1038/s41598-018-27377-2
Li Q, Yon JY, Cai H. Mechanisms and Consequences of eNOS Dysfunction in Hypertension. J Hypertension. 2016;33:1128–36.
doi: 10.1097/HJH.0000000000000587
Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharm Rev. 1991;43:109–42.
pubmed: 1852778
Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008;7:156–67.
doi: 10.1038/nrd2466
Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Asp Med. 2005;26:33–65.
doi: 10.1016/j.mam.2004.09.003
Reckelhoff JF, Kellum JA, Blanchard EJ, Bacon EE, Wesley AJ, Kruckeberg WC. Changes in nitric oxide precursor, L-arginine, and metabolites, nitrate and nitrite, with aging. Life Sci. 1994;55:1895–902.
doi: 10.1016/0024-3205(94)00521-4
Takase H, Sugiyama M, Nakazawa A, Sato K, Ueda R, Dohi Y. Long-term effect of antihypertensive therapy with calcium antagonist or angiotensin converting enzyme inhibitor on serum nitrite/nitrate levels in human essential hypertension. Arzneimittelforschung. 2000;50:530–4.
pubmed: 10918945
Wang H, Liu J. Plasma asymmetric dimethylarginine and L-arginine levels in Chinese patients with essential hypertension without coronary artery disease. J Cardiovasc Dis Res. 2011;2:177–80.
doi: 10.4103/0975-3583.85265
Glyn MC, Anderssohn M, Lüneberg N, Van Rooyen JM, Schutte R, Huisman HW, et al. Ethnic-specific differences in L-arginine status in South African men. J Hum Hypertens. 2012;26:737–43.
doi: 10.1038/jhh.2011.103
Mels CM, Huisman HW, Smith W, Schutte R, Schwedhelm E, Atzler D, et al. The relationship of nitric oxide synthesis capacity, oxidative stress, and albumin-to-creatinine ratio in black and white men: the SABPA study. Age. 2016;38:9.
doi: 10.1007/s11357-016-9873-6
Schutte AE, Schutte R, Huisman HW, Van Rooyen JM, Fourie CM, Malan L, et al. Dimethylarginines: their vascular and metabolic roles in African and Caucasians. Eur J Endocrinol. 2010;162:525–33.
doi: 10.1530/EJE-09-0865
Schutte AE, Gona PN, Delles C, Uys AS, Burger A, Mels CMC, et al. The African Prospective study on the early detection and identification of cardiovascular disease and hypertension (African-PREDICT): design, recruitment and initial examination. Eur. J Prev Cardiol. 2019;26:458–70.
doi: 10.1177/2047487318822354
Carlson RV, Boyd KM, Webb DJ. The revision of the Declaration of Helsinki: past, present and future. Br J Clin Pharm. 2004;57:659–713.
doi: 10.1111/j.1365-2125.2004.02103.x
Kiers HD, Hofstra JM, Wetzels JFM. Oscillometric blood pressure measurements: differences between measured and calculated mean arterial pressure. J Med. 2008;66:474–9.
Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30:445–8.
doi: 10.1097/HJH.0b013e32834fa8b0
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Eng J Med. 2012;367:20–29.
doi: 10.1056/NEJMoa1114248
Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem. 2005;51:1268–71.
doi: 10.1373/clinchem.2004.046037
Atzler D, Mieth M, Maas R, Böger RH, Schwedhelm E. Stable isotope dilution assay for liquid chromatography-tandem mass spectrometric determination of L-homoarginine in human plasma. J Chromatogr B Anal Technnol Biomed Life Sci. 2011;879:2294–8.
doi: 10.1016/j.jchromb.2011.06.016
Hanff E, Lützow M, Kayacelebi AA, Finkel A, Maassen M, Yanchev GR, et al. Simultaneous GC-ECNICI-MS measurement of nitrite, nitrate and creatinine in human urine and plasma in clinical settings. J Chromatogr B Anal Technol Biomed Life Sci. 2017a;2017:207–14.
doi: 10.1016/j.jchromb.2016.03.034
Tsikas D, Hanff E, Bollenbach A, Kruger R, Pham VV, Chobanyan-Jürgens K, et al. Results, meta-analysis and a first evaluation of UNOxR, the urinary nitrate-to-nitrite molar ratio, as a measure of nitrite reabsorption in experimental and clinical settings. Amino Acids. 2018;50:799–821.
doi: 10.1007/s00726-018-2573-z
Melikian N, Wheatcroft SB, Ogah OS, Murphy C, Chowienczyk PJ, Wierzbicki AS, et al. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men. Hypertension. 2007;49:873–7.
doi: 10.1161/01.HYP.0000258405.25330.80
Moss MB, Brunini TM, Soares De Moura R, Novaes Malagris LE, Roberts NB, Ellory JC, et al. Diminished L-arginine bioavailability in hypertension. Clin Sci. 2004;107:391–7.
doi: 10.1042/CS20030412
Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Böger RH, et al. Asymmetric dimethylarginine, L-arginine and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005;46:518–23.
doi: 10.1016/j.jacc.2005.04.040
Van der Zwan LP, Davids M, Scheffer PG, Dekker JM, Stehouwer CD. Teerlink T. L-Homoarginine and L-arginine are antagonistically related to blood pressure in elderly population: the Hoorn Study. J Hypertens. 2013;31:1114–23.
doi: 10.1097/HJH.0b013e32836037fb
Litwin M, Obrycki L, Niemirska A, Sarnecki J, Kulaga Z. Central systolic blood pressure and central pulse pressure predict left ventricular hypertrophy in hypertensive children. Pediatr Nephrol. 2019;34:703–12.
doi: 10.1007/s00467-018-4136-7
Schneider JY, Rothmann S, Schröder F, Langen J, Lücke T, Mariotti F, et al. Effects of chronic oral L-arginine administration on the L-arginine/NO pathway in patients with peripheral arterial occlusive disease or coronary artery disease: L-Arginine prevents renal loss of nitrite, the major NO reservoir. Amino Acids. 2005;47:1961–74.
doi: 10.1007/s00726-015-2031-0
Said MY, Bollenbach A, Minović I, Van Londen M, Frenay AR, de Borst MH, et al. Plasma ADMA, Urinary ADMA excretion, and late mortality in renal transplant recipients. Amino Acids. 2019;51:913–27.
doi: 10.1007/s00726-019-02725-2
Bode-Böger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol. 2006;17:1128–34.
doi: 10.1681/ASN.2005101119
Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, et al. Asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental. Hypertension Hypertension. 1997;29:242–7.
doi: 10.1161/01.HYP.29.1.242
Wolf C, Lorenzen JM, Stein S, Tsikas D, Störk S, Weidemann F, et al. Urinary asymmetric dimethylarginine (ADMA) is a predictor of mortality risk in patients with coronary artery disease. Int J Cardiol. 2012;156:289–94.
doi: 10.1016/j.ijcard.2010.11.003
Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Nikolaidou B, Anyfanti P, Koletsos N, et al. Asymmetric dimethylarginine levels associated with augmentation index across naïve untreated patients with different hypertension phenotypes. J Clin Hypertens. 2018;20:680–5.
doi: 10.1111/jch.13237
Serg M, Kampus P, Kals J, Zagura M, Muda P, Tuomainen TP, et al. Association between asymmetric dimethylarginine and indices of vascular function in patients with essential hypertension. Blood Press. 2011;20:111–6.
doi: 10.3109/08037051.2010.533821
Päivä H, Kähönen M, Lehtimäki T, Raitakari OT, Jula A, Viikari J, et al. Asymmetric Dimethylarginine (ADMA) has a role in regulating systemic vascular tone in young healthy subjects: the cardiovascular risk in Young Finn Study. Am J Hypertens. 2008;21:873–8.
doi: 10.1038/ajh.2008.215
Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetric dimethylarginine in humans. Circulation. 2004;109:172–7.
doi: 10.1161/01.CIR.0000105764.22626.B1